A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Here we report an integrated analysis that leverages data from treatment of genetic mouse models of prostate cancer along with clinical data from patients to elucidate new mechanisms of castration resistance. We show that castration counteracts tumor progression in a Pten loss–driven mouse model of prostate cancer through the induction of apoptosis and proliferation block. Conversely, this response is bypassed with deletion of either Trp53 or Zbtb7a together with Pten, leading to the development of castration-resistant prostate cancer (CRPC). Mechanistically, the integrated acquisition of data from mouse models and patients identifies the expression patterns of XAF1, XIAP and SRD5A1 as a predictive and actionable signature for CRPC. Notably, we show that combined inhibition of XIAP, SRD5A1 and AR pathways overcomes castration resistance. Thus, our co-clinical approach facilitates the stratification of patients and the development of tailored and innovative therapeutic treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · cited 1×
“22, where we observed a significant reduction in ZBTB7A expression in castrationresistant metastases (20) from several organs (Fig.”
BackgroundCrucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Self-citationWang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) · Nature · doi:10.1038/nature10937 · Cited by 446
Self-citationDihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
Chang, K.-H., Li, R., Papari-Zareei, M., Watumull, L., Zhao, Y. D., Auchus, R. J., & Sharifi, N. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107898108 · Cited by 346
Clinical significance of p53 alterations in surgically treated prostate cancers
Schlomm, T., Iwers, L., Kirstein, P., Jessen, B., Köllermann, J., Minner, S., Passow-Drolet, A., Mirlacher, M., Milde-Langosch, K., Graefen, M., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.104 · Cited by 196
Wang, G., Lunardi, A., Zhang, J., Chen, Z., Ala, U., Webster, K. A., Tay, Y., Gonzalez-Billalabeitia, E., Egia, A., Shaffer, D. R., et al. (2013) · Nature Genetics · doi:10.1038/ng.2654 · Cited by 137
Self-citation
Cited by
Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression
Wang, G., Lu, X., Dey, P., Deng, P., Wu, C. C., Jiang, S., Fang, Z., Zhao, K., Konaparthi, R., Hua, S., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0224 · Cited by 553
Self-citationGenetically engineered mouse models in oncology research and cancer medicine
Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606857 · Cited by 502
Patel, J. D., Krilov, L., Adams, S., Aghajanian, C., Basch, E., Brose, M. S., Carroll, W. L., de Lima, M., Gilbert, M. R., Kris, M. G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7076 · Cited by 434
Il-23 secreted by myeloid cells drives castration-resistant prostate cancer
Calcinotto, A., Spataro, C., Zagato, E., Di Mitri, D., Gil, V., Crespo, M., De Bernardis, G., Losa, M., Mirenda, M., Pasquini, E., et al. (2018) · Nature · doi:10.1038/s41586-018-0266-0 · Cited by 394
Zou, M., Toivanen, R., Mitrofanova, A., Floch, N., Hayati, S., Sun, Y., Le Magnen, C., Chester, D., Mostaghel, E. A., Califano, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1174 · Cited by 386
Copy number alteration burden predicts prostate cancer relapse
Hieronymus, H., Schultz, N., Gopalan, A., Carver, B. S., Chang, M. T., Xiao, Y., Heguy, A., Huberman, K., Bernstein, M., Assel, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411446111 · Cited by 364
Lee, Y.-R., Chen, M., Lee, J. D., Zhang, J., Lin, S.-Y., Fu, T.-M., Chen, H., Ishikawa, T., Chiang, S.-Y., Katon, J., et al. (2019) · Science · doi:10.1126/science.aau0159 · Cited by 329
Self-citationDu, Z., Sun, T., Hacisuleyman, E., Fei, T., Wang, X., Brown, M., Rinn, J. L., Lee, M. G.-S., Chen, Y., Kantoff, P. W., et al. (2016) · Nature Communications · doi:10.1038/ncomms10982 · Cited by 317
An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer
Chen, M., Zhang, J., Sampieri, K., Clohessy, J. G., Mendez, L., Gonzalez-Billalabeitia, E., Liu, X.-S., Lee, Y.-R., Fung, J., Katon, J. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-017-0027-2 · Cited by 293
Self-citationOne mouse, one patient paradigm: New avatars of personalized cancer therapy
Malaney, P., Nicosia, S. V., & Davé, V. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.10.010 · Cited by 289
Wang, L., Xiong, H., Wu, F., Zhang, Y., Wang, J., Zhao, L., Guo, X., Chang, L.-J., Zhang, Y., You, M. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.053 · Cited by 288
PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
Hsieh, A., & Edlind, M. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122876 · Cited by 276
Wang, G., Lunardi, A., Zhang, J., Chen, Z., Ala, U., Webster, K. A., Tay, Y., Gonzalez-Billalabeitia, E., Egia, A., Shaffer, D. R., et al. (2013) · Nature Genetics · doi:10.1038/ng.2654 · Cited by 137
“…associated with PTEN loss in advanced prostate tumors, it is conceivable that ZBTB7A might have important oncosuppressive functions in the context of TMPRSS2 - ERG fusion or TP53 loss or mutation in counteracting the progression of prostate tumors as well as the response to specific treatments 49 .”
Self-citation
Metadata
- Authors
- Lunardi, A., Ala, U., Epping, M. T., Salmena, L., Clohessy, J. G., Webster, K. A., Wang, G., Mazzucchelli, R., Bianconi, M., Stack, E. C., Lis, R., Patnaik, A., Cantley, L. C., Bubley, G., Cordon-Cardo, C., Gerald, W. L., Montironi, R., Signoretti, S., Loda, M., Nardella, C., & Pandolfi, P. P.
- Venue
- Nature Genetics
- Published
- 2013-06-02
- Volume
- 45
- Issue
- 7
- Pages
- 747-755
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2151419509
- Cited by
- 144
- References
- 7
- FWCI
- 15.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.